1. Department of Pharmacy, Changzhou Third People's Hospital, Changzhou, Jiangsu 213000, China; 2. Changzhou Third People's Hospital, Changzhou, Jiangsu 213000, China; 3. Changzhou Center for Disease Control and Prevention, Control, Changzhou, Jiangsu 213000, China
Abstract：Objective To investigate the rifampicin resistance status and its influencing factors among elderly patients with pulmonary tuberculosis in Changzhou City, Jiangsu Province, so as to provide the basis for improving drug-resistant pulmonary tuberculosis prevention and control strategies. Methods Patients aged over 60 years with pulmonary tuberculosis treated in tuberculosis designated hospital was selected. Demographic information, history of previous disease, history of diagnosis and treatment and drug sensitivity test were collected. Rifampicin resistance among elderly patients with pulmonary tuberculosis and its influencing factors was analyzed. Results Totally 249 elderly patients with pulmonary tuberculosis were included, with an average of (69.75±4.36) years. There were 147 males and 102 females, with a gender ratio of 1.44∶1. There were 183 treatment-naïve patients (73.49%) and 66 retreated patients (26.51%). Rifampicin resistance was found in 21 cases, with a drug resistance rate of 8.43%. Among them, there were 7 treatment-naïve patients (3.83%), and 14 retreated patients (21.21%). Multivariable logistic regression analysis showed that retreated elderly patients with pulmonary tuberculosis had a higher risk of rifampicin resistance (OR=10.551, 95%CI: 1.344-82.857). Conclusion The rifampicin resistance rate of 249 elderly patients with pulmonary tuberculosis was 8.43% and was associated with the type of treatment.
[1] World Health Organization.Global tuberculosis report 2022[R/OL].[2024-01-08]. https://www.who.int/teams/global-tuberculosis-programme/TB-reports/global-tuberculosis-report-2022. [2] World Health Organization.WHO consolidated guidelines on tuberculosis. Module 4:treatment-drug-resistant tuberculosis treatment,2022 update[M]. Geneva:WHO,2022. [3] LIANG S F,MA J C,WANG G,et al.The application of artificial intelligence in the diagnosis and drug resistance prediction of pulmonary tuberculosis[J/OL]. Front Med,2022,9 [2024-01-08]. https://doi.org/10.3389/fmed.2022.935080. [4] 舒薇,逄宇,高静韬,等. 中华医学会结核病学分会2022年全国结核病学术大会会议纪要[J]. 中华结核和呼吸杂志,2022,45(11):1156-1160. [5] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. 肺结核基层诊疗指南(2018年)[J]. 中华全科医师杂志,2019,18(8):709-717. [6] 赵雁林. 结核病实验室质量保证手册[M]. 北京:人民卫生出版社,2017. [7] ASLAM B,KHURSHID M,ARSHAD M I,et al.Antibiotic resistance:one health one world outlook[J/OL]. Front Cell Infect Microbiol,2021,11 [2024-01-08]. https://doi.org/10.3389/fcimb.2021.771510. [8] DEVOID I,SILLAH A K,SUTHERLAND J,et al.The household economic burden of drug-susceptible TB diagnosis and treatment in the Gambia[J]. Int J Tuberc Lung Dis,2022,26(12):1162-1169. [9] AIA P,VINEY K,KAL M,et al.The economic burden of TB faced by patients and affected families in Papua New Guinea[J]. Int J Tuberc Lung Dis,2022,26(10):934-941. [10] TRAUER J M.Targeted TB control in migrants to low-burden countries[J]. Int J Tuberc Lung Dis,2023,27(3):169-170. [11] 王远航,胡洁,葛锐,等. 嘉兴市结核分枝杆菌耐药情况分析[J]. 预防医学,2023,35(8):705-709. [12] 李仁忠,阮云洲,徐彩红,等. 世界卫生组织利福平耐药结核病患者数估算方法[J]. 中国防痨杂志,2023,45(3):328. [13] 何昱颖,胡屹,陈玮,等. 2014年至2018年贵州省利福平耐药结核病的危险因素及治疗转归分析[J]. 中华传染病杂志,2021,39(5):289-294. [14] 王荣,杨晨,丁松宁,等. 南京市复治涂阳肺结核患者耐药状况分析[J]. 预防医学,2019,31(5):478-481. [15] MUTAYOBA B K,ERSHOVA J,LYAMUYA E,et al.The second national anti-tuberculosis drug resistance survey in Tanzania,2017-2018[J]. Trop Med Int Health,2022,27(10):891-901. [16] DE VOS M,SCOTT L,DAVID A,et al. Comparative analytical evaluation of four centralized platforms for the detection of Mycobacterium tuberculosis complex and resistance to rifampicin and isoniazid[J/OL]. J Clin Microbiol,2021,59(3) [2024-01-08]. https://doi.org/10.1128/JCM.02168-20.
